Skip to main content
. 2021 Mar 16;13(3):215. doi: 10.3390/toxins13030215

Figure 2.

Figure 2

The mean ± standard error (SE) by year of disease-specific QoL (HF30) with significant linear model (p = 0.0001) (top left); the abnormal involuntary movement scale (AIMS) with significant linear model (p = 0.008) (top right); general health QoL (SF-36) showed significant linear model (p = 0.002) after injections of Abo-BTX A (bottom left); and the mean ± standard (SE) by year of Center of Epidemiologic Studies-Depression (CES-D) questionnaire showed no significant improvement after injections of Abo-BTX A (p = 0.191) (bottom right).